Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

4.485 +0.095 (+2.16%)
Streaming Delayed Price Updated: 9:38 AM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vanda Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate
FDA denies Vanda's Tradipitant application for gastroparesis, urging new trials for efficacy and safety. Vanda disputes the agency's review process. 
Via Benzinga
Exposures Product Safety
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product portfolio, and growth in neurology. 
Via Benzinga
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
A regulator's decision drained the market's enthusiasm for the company. 
Via The Motley Fool
FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies
The FDA rejected Vanda Pharmaceuticals' new drug application for tradipitant to treat gastroparesis, citing the need for more studies despite delays in its review process. Vanda argues the drug meets... 
Via Benzinga
Exposures Product Safety
What's Going On With Vanda Pharmaceuticals Shares Today?
Vanda Pharmaceuticals shares decline as Future Pak withdraws acquisition offer following Vanda's rejection and lack of response. 
Via Benzinga
Why Vanda Pharmaceuticals Stock Is Skyrocketing Today
Future Pak wants Vanda, but Vanda doesn't want Future Pak. 
Via The Motley Fool
Earnings Scheduled For May 7, 2025
Via Benzinga
A Glimpse of Vanda Pharma's Earnings Potential
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals
Via Benzinga
The Analyst Verdict: Vanda Pharma In The Eyes Of 5 Experts
Via Benzinga
Earnings Scheduled For February 13, 2025
Via Benzinga
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts
Via Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
Via Benzinga
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal
Cycle Pharmaceuticals wants to acquire Vanda Pharmaceuticals for $8 per share, or $466 million. Cycle focuses on rare neurological conditions. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning! 
Via InvestorPlace
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
VNDA Stock Earnings: Vanda Pharma Misses EPS, Misses Revenue for Q1 2024
VNDA stock results show that Vanda Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact." 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21.... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share
Vanda Pharmaceuticals rebuffs unsolicited proposals from Future Pak LLC, citing undervaluation. Offers up to $7.75 per share. Board asserts resilient business with FDA-approved products. Future Pak... 
Via Benzinga
Why Is Trio Petroleum (TPET) Stock Down 22% Today?
Trio Petroleum stock is falling on Wednesday as TPET investors learn of a securities purchase agreement and Senior Secured Note. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.